medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (2)


More Evidence for the Genetic Susceptibility of Mexican Population to Nonalcoholic Fatty Liver Disease through PNPLA3

Chinchilla-López P, Ramírez-Pérez O, Cruz-Ramón V, Canizales-Quinteros S, Domínguez-López A, Ponciano-Rodríguez G, Sánchez-Muñoz F, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 250-255
Archivo PDF: 1829.82 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. López-Velazquez JA, Silva-Vidal KV, Ponciano-Rodriguez G, Chavez-Tapia NC, Arrese M, Uribe M, Méndez-Sánchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol 2014; 2: 166-78.

  2. Mendez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver International 2007; 4:423-33.

  3. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-94 36.

  4. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111-16.

  5. 5 Romeo S, Kozlitina J, Xing Ch, Pertsemlidis A, Cox D, Pennacchio LA, BoerwinkleE, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 12: 1461-5.

  6. 6 Hernaez R, McLean J, Lazo M, Brancati FL, Hirschhorn JN, Borecki IB, Harris TB, et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol 2013; 9: 1183-90.

  7. Martínez LA, Larrieta E, Calva JJ, Kershenobich D, Torre A. The expression of PNPLA3 Polymorphism could be the key for severe Liver Disease in NAFLD in Hispanic Population. Annals of Hepatol 2017; 6: 909-15.

  8. Larrieta-Carrasco E, Acuña-Alonzo V, Velazquez-Cruz R, Barquera-Lozano R, León-Mimila P, Villamil-Ramýrez H, Menjivar M, et al. PNPLA3 I148M polymorphism is associated with elevated alanine transaminase levels in Mexican Indigenous and Mestizo populations. Mol Biol Rep 2014; 7: 4705-11.

  9. León-Mimila P, Vega-Badillo J, Gutiérrez-Vidal R, Villamil-Ramírez H, Villareal-Molina T, Larrieta-Carrasco E, López-Contreras BE, et al. Genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity. Exp Mol Pathol 2015; 2: 178-83.

  10. Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Sci Rep 2015; 5: 9284.

  11. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014; 3: 325-34.

  12. Norden-Krichmar TM, Gizer IR, Libiger O, Wilhelmsen KC, Ehlers CL, Schork NJ. Correlation analysis of genetic admixture and social identification with body mass index in a Native American community. Am J Hum Biol 2014; 26: 347-60.

  13. Martinez-Marignac VL, Valladares A, Cameron E, Chan A, Perera A, Globus-Goldberg R, Wacher N, et al. Admixture in Mexico City: Implications for admixture mapping of type 2 diabetes genetic risk factors. Hum Genet 2007; 120: 807-19.

  14. Garner C, Conn C, Cohen D, Luo L, Castillo JJ, Shah V, Garver W. NAFLD susceptibility genes and their association with type 2 diabetes and obesity in a New Mexico population. J Diabetes Obes 2015; 2: 10.15436/2376-0494.15.024.

  15. Rojas A, Gallego P, Gil-Gómez A, Muñoz-Hernández R, Rojas L, Maldonado R, Gallego-Durán R, et al. Natural Extracts Abolish Lipid Accumulation in Cells Harbouring Non-Favourable PNPLA3 genotype. Ann of Hepatol 2018; 2 [In press].

  16. Konerman MA, Jones J, Harrison SA. Pharmacotherapy for NASH: Current and emerging. Journal of Hepatology 2018; 68: 362-75.

  17. Escobedo-de la Peña J, de Jesús-Pérez R, Schargrodsky H, Champagne B. Prevalence of dyslipidemias in Mexico city and Its relation to other cardiovascular risk factors. Gac Med Mex 2014; 2: 128-36.

  18. Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Pública de México 2010; 52: S1 44-53.

  19. Palloni A, Beltrán-Sánchez H, Novak B, Pinto G, Wong R. Adult Obesity, disease and longevity in Mexico. Salud Pública Mex 2015; Supp. 1: S22-30

  20. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016 Informe Final de Resultados. Available on: http://oment.uanl.mx/wp-content/uploads/ 2016/12/ensanut_mc_2016-310oct.pdf Accessed: January 26th, 2018.

  21. World Health Organization – Diabetes country profiles, 2016. Available on: http://www.who.int/diabetes/country-profiles/ mex_en.pdf Accessed: January 26th, 2018

  22. Meza R, Barrientos-Gutierrez T, Rojas-Martinez R, Palacio- Mejia LS, Lazcano-Ponce E, Hernández-Ávila M. Burden of Type 2 Diabetes in Mexico: Past, Current and Future Prevalence and Incidence Rates. Prev Med 2015; 81: 445-50.




2020     |     www.medigraphic.com